Spinocerebellar Ataxia Type 3 Sca3 clinical trials

Explore recruiting spinocerebellar ataxia type 3 sca3 clinical trials.

Recruiting spinocerebellar ataxia type 3 sca3 studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Spinocerebellar Ataxia Type 3 Sca3 trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL TO ASSESS SAFETY AND EFFICACY OF SLS-005 (TREHALOSE INJECTION, 90.5 MG/ML FOR INTRAVENOUS INFUSION) FOR THE TREATMENT OF ADULTS WITH SPINOCEREBELLAR ATAXIA

Spain, Portugal, Germany

Phase II and Phase III (Integrated) EU CTIS Study details

Spinocerebellar Ataxia Type 3 Sca3 trials by city

Spinocerebellar Ataxia Type 3 Sca3 in Toronto Spinocerebellar Ataxia Type 3 Sca3 in Vancouver Spinocerebellar Ataxia Type 3 Sca3 in Montreal Spinocerebellar Ataxia Type 3 Sca3 in Calgary Spinocerebellar Ataxia Type 3 Sca3 in Edmonton Spinocerebellar Ataxia Type 3 Sca3 in Ottawa Spinocerebellar Ataxia Type 3 Sca3 in Winnipeg Spinocerebellar Ataxia Type 3 Sca3 in Quebec City Spinocerebellar Ataxia Type 3 Sca3 in Hamilton Spinocerebellar Ataxia Type 3 Sca3 in Kitchener Spinocerebellar Ataxia Type 3 Sca3 in London Spinocerebellar Ataxia Type 3 Sca3 in Halifax Spinocerebellar Ataxia Type 3 Sca3 in New York Spinocerebellar Ataxia Type 3 Sca3 in Los Angeles Spinocerebellar Ataxia Type 3 Sca3 in Chicago Spinocerebellar Ataxia Type 3 Sca3 in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease